Datwyler with strategic acquisitions for the future
Datwyler delivered a solid performance in the first half of 2022 in a difficult environment thanks to strong market positions.
18 results for ReportClear filter
Datwyler with further progress in sustainability
14th sustainability report in accordance with GRI guidelines.
Why Pharma Should be Focusing on ESG
Learn more about how the pharma industry is taking charge to improve environmental, social, and governance (ESG) critical issues.
Focused Datwyler achieves profitable growth
Datwyler is now focusing exclusively on system-critical elastomer components. The continuing operations generated record revenue and currency-adjusted growth of 15.0%.
Datwyler enhances sustainability strategy.
With twelve focus topics, the company aims to reduce its environmental footprint and create added value for all stakeholders.
Datwyler accelerates its profitable growth.
Despite the ongoing uncertainty caused by the pandemic, Datwyler has increased its forecasts for the year as a whole for revenue and EBIT margin to over CHF 1’150 million and above 16%, respectively.
Datwyler performs strongly in extraordinary times.
Datwyler reports solid profitability in extraordinary times.
«New» Datwyler with significantly higher margin.
Datwyler achieves a good result in a difficult environment.
Datwyler continues its profitable growth course.